Skip to main content

Table 5 Changes in serum electrolytes and PTH among studied patients

From: The efficacy and safety of niacin on hyperphosphatemia in ESRD patients undergoing hemodialysis: randomized controlled trial

 

Niacin group

(n = 25)

Control group

(n = 25)

P value

Calcium (mg/dl)

 Baseline

8.60 ± 0.96

8.86 ± 0.74

0.37

 At 3rd month

8.87 ± 0.56

9.62 ± 0.54

< 0.001

 At 6th month

8.92 ± 0.55

10.53 ± 0.77

< 0.001

Phosphorous (mEq/l)

 Baseline

6.88 ± 0.86

6.95 ± 0.92

0.80

 At 3rd month

5.90 ± 0.52

6.42 ± 0.65

< 0.001

 At 6th month

5.12 ± 0.41

5.76 ± 0.47

< 0.001

ALP (μ/l)

 Baseline

182.52 ± 67.89

299.25 ± 98.87

0.05

 At 3rd month

216.52 ± 58.90

223.81 ± 47.08

0.88

 At 6th month

169.96 ± 44.56

158.06 ± 65.10

0.68

PTH (pg/ml)

 Baseline

284.17 ± 98.46

312.87 ± 65.89

0.40

 At 3rd month

192.39 ± 78.85

388.27 ± 263.10

< 0.001

 At 6th month

127.56 ± 90.87

249.85 ± 97.69

0.01

  1. Data expressed as mean (SD). P value was significant if < 0.05. PTH parathormone hormone